929302-01-2

Usage

Uses

Used in Pharmaceutical Industry:
9-Benzyl-3,9-diaza-spiro[5.5]undecane-3-carboxylic acid tert-butyl ester is used as a potential pharmaceutical agent for its diverse biological activities. 9-BENZYL-3,9-DIAZA-SPIRO[5.5]UNDECANE-3-CARBOXYLIC ACID TERT-BUTYL ESTER's unique structure and properties may contribute to the development of new drugs and therapeutic agents.
Used in Drug Discovery:
In the field of drug discovery, 9-Benzyl-3,9-diaza-spiro[5.5]undecane-3-carboxylic acid tert-butyl ester serves as a valuable chemical entity for the synthesis of new chemical entities. Its potential biological activities and unique structural features make it a promising candidate for further research and development.
Used in Chemical Synthesis:
9-Benzyl-3,9-diaza-spiro[5.5]undecane-3-carboxylic acid tert-butyl ester is utilized in chemical synthesis processes to create novel compounds with potential applications in various industries, including pharmaceuticals, materials science, and agrochemicals.
It is important to handle 9-Benzyl-3,9-diaza-spiro[5.5]undecane-3-carboxylic acid tert-butyl ester with care due to potential hazards associated with its use. Proper safety measures should be taken during its synthesis, storage, and application to minimize any risks.

InChI:InChI=1/C21H32N2O2/c1-20(2,3)25-19(24)23-15-11-21(12-16-23)9-13-22(14-10-21)17-18-7-5-4-6-8-18/h4-8H,9-17H2,1-3H3

Upstream product

• 100-52-7 benzaldehyde 
• 173405-78-2 tert-butyl 3,9-diazaspiro[5.5]undecane-3-carboxylate 
• 3612-20-2 1-phenylmethyl-4-piperidone 
• 189333-46-8 9-benzyl-2,4-dioxo-3,9-diazaspiro[5,5]undecane-1,5-dicarbonitrile 
• 189333-49-1 3-benzyl-3,9-diazaspiro[5.5]undecane 
• 24424-99-5 di-tert-butyl dicarbonate 
• 170228-79-2 tert-butyl 4,4-bis(2-((methylsulfonyl)oxy)ethyl)piperidine-1-carboxylate 
• 100-46-9 benzylamine 

Downstream Products

• 189333-49-1 3-benzyl-3,9-diazaspiro[5.5]undecane 
• 173405-78-2 tert-butyl 3,9-diazaspiro[5.5]undecane-3-carboxylate 
• 236406-47-6 3,9-diazaspiro[5.5]undecane-3-carboxylic acid tert-butyl ester hydrochloride 

Relevant academic research and scientific papers

1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONE DERIVATIVE AS WEE1 INHIBITOR

The present invention provides a 1,2-dihydro-3H-pyrazolo[3,4-d]pyrimidin-3-one compound having an inhibitory effect on Wee 1, and includes an application of the compound in treating various types of tumors.

Identification of Better Pharmacokinetic Benzothiazinone Derivatives as New Antitubercular Agents

A series of new 8-nitro-6-(trifluoromethyl)-1,3-benzothiazin-4-one(BTZ) derivatives containing a C-2 nitrogen spiro-heterocycle moiety based on the structures of BTZ candidates BTZ043 and PBTZ169 were designed and synthesized as new antitubercular agents. Many of them were found to have excellent in vitro activity (MIC 0.15 μM) against the drug susceptive Mycobacterium tuberculosis H37Rv strain and two clinically isolated multidrug-resistant strains. Compounds 11l and 11m display acceptable safety, greater aqueous solubility, and better pharmacokinetic profiles than PBTZ169, suggesting their promising potential to be lead compounds for future antitubercular drug discovery.

INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL

The present invention provides compounds of Formula I and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention.

INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL

The present invention provides compounds of Formula I and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention.

INHIBITORS OF RENAL OUTER MEDULLARY POTASSIUM CHANNEL

Novel spirocyclic compounds of formula I: and pharmaceutically acceptable salts thereof are disclosed as inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention. Pharmaceutical compositions and methods of treatment are also included.

INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL

Novel spirocyclic compounds of formula I: and pharmaceutically acceptable salts thereof are disclosed as inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention. Pharmaceutical compositions and methods of treatment are also included.

NOVEL DIAZASPIROALKANES AND THEIR USE FOR TREATMENT OF CCR8 MEDIATED DISEASES

The invention provides compounds of general formula (I) wherein A, B, p, w, x, y, and z are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.